HKHenrike E. Karim-Kos

Henrike E. Karim-Kos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henrike E. Karim-Kos has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiology of childhood and adolescent cancer in Bangladesh, 2001–2014

    by Mohammad Sorowar Hossain, Mamtaz Begum, Mahmuduzzaman Mian, Shameema Ferdous, Shahinur Kabir, Humayun Kabir Sarker, Sabina Karim, Salma Choudhury, Asaduzzaman Khan, Zohora Jameela Khan, et al.

    Cancer burden among children and adolescents is largely unknown in Bangladesh. This study aims to provide a comprehensive overview on childhood and adolescent cancers and to contribute to the future strategies to deal with these diseases in Bangladesh. Data on malignant neoplasms in patients aged less than 20 years diagnosed between 2001 and 2014 (N = 3143) in Bangladesh was collected by the National Institute of Cancer Research and Hospital and ASHIC Foundation. The age pattern and distribution of cancer types were analysed and the incidence rates were calculated. The age-standardised incidence rate was 7.8 per million person-years for children (0–14 years) in the last time period (2011–2014). Retinoblastoma (25 %) and leukaemia (18 %) were the most common childhood cancers. For adolescents (15–19 years), the age-specific incidence rate was 2.1 per million person-years in the same time period. Most common adolescent cancers were malignant bone tumours (38 %), germ cell and gonadal tumours (17 %), and epithelial tumours (16 %). There were more boys affected (M: F ratio 2.0 in children and 1.4 in adolescents) than girls. Cancer incidences were lower than expected most likely due to a low level of awareness about cancer among clinicians and the population, inadequate access to health care, lack of diagnostic equipment and incomplete recording of cases. Improvements on different levels should be made to get a better epidemiologic insight and to detect cancer earlier resulting in a better outcome for affected children and adolescents.


  • Open Access

    Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation

    by Henrike E. Karim‐Kos, Lambertus A.L.M. Kiemeney, Marieke W.J. Louwman, Jan Willem W. Coebergh, Esther de Vries

    Progress against cancer through prevention and treatment is often measured by survival statistics only instead of analyzing trends in incidence, survival and mortality simultaneously because of interactive influences. This study combines these parameters of major cancers to provide an overview of the progress achieved in the Netherlands since 1989 and to establish in which areas action is needed. The population‐based Netherlands Cancer Registry and Statistics Netherlands provided incidence, 5‐year relative survival and mortality of 23 major cancer types. Incidence, survival and mortality changes were calculated as the estimated annual percentage change. Optimal progress was defined as decreasing incidence and/or improving survival accompanied by declining mortality, and deterioration as increasing incidence and/or deteriorating survival accompanied by increasing mortality rates. Optimal progress was observed in 12 of 19 cancer types among males: laryngeal, lung, stomach, gallbladder, colon, rectal, bladder, prostate and thyroid cancer, leukemia, Hodgkin and non‐Hodgkin lymphoma. Among females, optimal progress was observed in 12 of 21 cancers: stomach, gallbladder, colon, rectal, breast, cervical, uterus, ovarian and thyroid cancer, leukemia, Hodgkin and non‐Hodgkin lymphoma. Deterioration occurred in three cancer types among males: skin melanoma, esophageal and kidney cancer, and among females six cancer types: skin melanoma, oral cavity, pharyngeal, esophageal, pancreatic and lung cancer. Our conceptual framework limits misinterpretations from separate trends and generates a more balanced discussion on progress.


  • 1023 HEPATOCELLULAR CARCINOMA IN THE NETHERLANDS: CHANGES IN INCIDENCE, TREATMENT AND SURVIVAL DURING THE LAST TWO DECADES

    by C.D.M. Witjes, S.A.W. van Den Akker, O. Visser, H.E. Karim-Kos, E. de Vries, J.N.M. Ijzermans, R.A. de Man, J.-W. Coebergh, C. Verhoef

  • Top Cited Papers

    Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

    by Henrike E. Karim-Kos, Esther de Vries, Isabelle Soerjomataram, Valery Lemmens, Sabine Siesling, Jan Willem W. Coebergh


    • 28 June 2008
      • Vol. 152  (26) , 1473-7

    [The beginning of the end of the lung cancer epidemic among Dutch women].

    by H E Karim-Kos, M L G Janssen-Heijnen, C A Van Iersel, R M Van Der Meer, E De Vries, J W W Coebergh

    To describe and interpret recent changes in lung cancer mortality and incidence, and changes in smoking prevalence among young and middle-aged women in The Netherlands. Secondary data analysis. Mortality data were collected from Statistics Netherlands (CBS; 1960-2006), data on the incidence were obtained from The Netherlands Cancer Registry (NCR; 1989-2003), and data on smoking prevalence were collected from the Dutch Foundation on Smoking and Health (STIVORO; 1988-2007). Mortality and incidence rates were calculated for four age groups (20-44, 45-49, 50-54 and 55-59 years). Changes in trends in mortality and smoking prevalence were examined using joinpoint regression and birth cohort analysis. Since the 1960s, lung cancer mortality and incidence has increased dramatically among women in The Netherlands. In the mid-1990s, lung cancer mortality and incidence rates in young women (aged < 50 years) surpassed those in men. Mortality rates in young women (aged 20-49 years) increased 4-6% annually. However, these rates started to stabilise since 1999. Among women born after 1950, mortality rates and smoking prevalence have decreased. An end to the lung cancer epidemic in women in The Netherlands is in sight. The first indications are the recent reduction in mortality and incidence among young women, particularly in women born after 1950. In the future, this reduction is expected to translate into a stabilisation or modest decrease in total lung cancer mortality and incidence.

  • Open Access

    The beginning of the end of the lung cancer epidemic in Dutch women?

    by Henrike E. Karim‐Kos, Maryska L.G. Janssen‐Heijnen, Carola A. van Iersel, Regina M. van der Meer, Esther de Vries, Jan Willem W. Coebergh

    In some European countries, female lung cancer mortality and incidence have started to decrease or flatten out, whereas they are still rising in The Netherlands. We present recent mortality and incidence trends of lung cancer and smoking trends in The Netherlands to show the end of the lung cancer epidemic in Dutch women. Lung cancer mortality and incidence rates by gender were analyzed for 4 age groups (20–44, 45–49, 50–54 and 55–59), and smoking prevalence rates were examined for women using joinpoint regression and birth cohort analysis. Data on mortality were collected for the period 1960–2006, incidence for the period 1989–2003 and smoking prevalence for the period 1988–2007. Because of decreasing lung cancer mortality and incidence rates among males and dramatically increasing rates among females, rates of young males were surpassed by those of females after the mid‐1990s. However, although in young women (20–49) mortality increased with 4–5% per year, it flattened out (no significant in‐ or decreases) since 1999. Among older women, mortality rates were still increasing markedly. Mortality rates and smoking prevalence tended to decrease in women born after the 1950s. This is the first report suggesting that the lung cancer epidemic in Dutch women is coming to an end. Although the increase in lung cancer incidence and mortality among Dutch women has been one of the most dramatic in Europe, the recent decrease in young women is expected to be followed by a future leveling off or a slight decrease in overall female lung cancer rates.